Form 4: Pfizer Executive Christoffel Boshoff Reports Stock Transaction

Christoffel Boshoff, President of R&D at Pfizer, reports the withholding of shares to cover tax obligations upon vesting of restricted stock units.

Summary

• Christoffel Boshoff, President of R&D at Pfizer, filed a Form 4 on February 4, 2025.
• The form reports a transaction that occurred on January 31, 2025.
• The transaction involved the withholding of 12,038 common stock shares to satisfy tax obligations related to the vesting of restricted stock units.
• The price per share for the transaction was $26.52.
• Following the transaction, Boshoff directly owns 150,344 shares of common stock and indirectly owns 664 shares through a Rule 16b-3 plan.

Sentiment

Score: 5

Explanation: This is a neutral regulatory filing. It doesn't indicate positive or negative sentiment, just a routine transaction.

Industry Context

Form 4 filings are a routine part of regulatory compliance for corporate insiders and provide transparency into their transactions in company stock. This filing indicates that a Pfizer executive has sold shares to cover tax obligations arising from vested stock awards, which is a common practice.

Key Dates

Keywords

Form 4, insider trading, stock transaction, Christoffel Boshoff, Pfizer, PFE, restricted stock units, tax obligations